Indications -- Psoriasis/Chronic Inflammation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: teevee	10/5/2006 12:40:59 PM
	of 631

Isotechnika successfully extends trial of ISA247 2006-10-05 09:24 ET - News Release Dr. Randall Yatscoff reports ISOTECHNIKA REPORTS FINAL SAFETY AND EFFICACY DATA FROM PHASE III PSORIASIS EXTENSION TRIAL Isotechnika Inc. has received final safety and efficacy data subsequent to 60 weeks of continuous treatment with ISA247. All safety and efficacy end points were met. Patients completing the 24-week Canadian phase III SPIRIT trial were given the opportunity to continue ISA247 therapy at a 0.3-milligram-per-kilogram twice-daily oral dose for an additional 36 weeks. The goal of the extension trial was to gather long-term safety data while demonstrating continued therapeutic benefit. Patients have now received continuous treatment with ISA247 for a total of 60 weeks. Over the course of the 24-week phase III trial, patients exhibited a 60-per-cent mean improvement in psoriasis area and severity index (PASI) scores. After an additional 36 weeks of treatment, there was a 54-per-cent mean improvement in PASI scores indicating continued therapeutic benefit. This beneficial effect was still observed 12 weeks after discontinuing ISA247 treatment; mean PASI scores remained at 35 per cent below pretreatment scores. Subsequent to 60 weeks of continuous treatment, there were no clinically significant changes in kidney function, cholesterol, triglycerides, new onset diabetes, infectious complications or other laboratory parameters. This supports the long-term safety of ISA247. "The heartening experience portending a new psoriasis medication continues as the efficacy and safety are confirmed in a longer study," stated Dr. Robert Auerbach, clinical professor of dermatology, New York University School of Medicine. "We are pleased that the final 60-week data is consistent with all previously reported data on the drug," added Dr. Randall Yatscoff, Isotechnika's president and chief executive officer. "The purpose of the extension trial was to generate longer-term safety and efficacy data. All of the end points of this trial have been successfully achieved. In addition, the majority of patients exhibited continued therapeutic benefit subsequent to discontinuation of drug." Dr. Yatscoff will present the final 60-week data at BioContact at 2:30 p.m. ET/12:30 p.m. MT this afternoon. All interested parties are encouraged to view the presentation on the company's website. The presentation will be loaded onto the website in conjunction with Dr. Yatscoff's live presentation. We seek Safe Harbor.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next